Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | BRAF | P15056 | 1/20 | 0.59 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | CSF1R | P07333 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12412116 | 0.92 | GRM5 (0.67) | GRM5ALDH1A1BRAFCSF1RSMN1; SMN2 | |
| SCHEMBL12416401 | 0.88 | GRM5 (0.74) | GRM5NT5E | |
| SCHEMBL12412109 | 0.88 | GRM5 (0.62) | GRM5ALDH1A1BRAFNT5ESMN1; SMN2 | |
| SCHEMBL12412108 | 0.87 | GRM5 (0.67) | GRM5ALDH1A1NT5ECSF1RSMN1; SMN2 | |
| SCHEMBL12412147 | 0.87 | GRM5 (0.61) | GRM5ALDH1A1BRAFNT5ESMN1; SMN2 | |
| SCHEMBL12412113 | 0.87 | GRM5 (0.67) | GRM5ALDH1A1BRAFNT5ESMN1; SMN2 | |
| SCHEMBL6925812 | 0.86 | GRM5 (1.00) | GRM5ALDH1A1CSF1RSMN1; SMN2LMNA | |
| SCHEMBL1487647 | 0.86 | GRM5 (1.00) | GRM5ALDH1A1BRAFCSF1R | |
| SCHEMBL6926437 | 0.86 | GRM5 (0.76) | GRM5ALDH1A1SMN1; SMN2TSHRLMNA | |
| SCHEMBL12503387 | 0.85 | CYP1A2 (0.62) | GRM5NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569308-B2 | Substituted heteroarylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | VANDERBILT UNIVERSITY (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110172247-A1 | SUBSTITUTED HETEROARYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172247-A1 | SUBSTITUTED HETEROARYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRM2 | GRM5 1/4885ALDH1A1 4696/4885BRAF 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.